Pheochromocytoma
ICD-10 E27.5 · ICD-11 5A75

Large or Invasive Pheochromocytoma: What to Do When Initial Preoperative Blockade Has Not Normalized Blood Pressure

In pheochromocytoma with a tumor larger than 6 cm, or in invasive pheochromocytoma, reaching the required preoperative blood pressure and heart rate targets can be challenging. When first-line blockade does not fully achieve those goals, a structured next-step approach is required before surgery can proceed safely.

Clinical Scenario

This protocol applies to patients with a pheochromocytoma larger than 6 cm or with evidence of local invasion. Open surgical resection is recommended in this population to ensure complete tumor removal, prevent tumor rupture, and avoid local recurrence.

Previous step insufficient
Initial Preoperative Blockade — Targets Not Yet Met

The first-line approach — α-adrenergic receptor blockade (phenoxybenzamine or doxazosin), together with high-sodium diet, fluid loading, and β-adrenergic receptor blockers (propranolol or atenolol) for tachycardia control — targets a blood pressure below 130/80 mm Hg while seated (systolic above 90 mm Hg standing) and a heart rate of 60–70 bpm seated, 70–80 bpm standing. This protocol is indicated when those targets have not been achieved.

Next-Step Treatment & Goals

Adding a calcium channel blocker to the existing α-adrenergic receptor blockade is the central next step for achieving further blood pressure control — additional options are also available for cases that require further stabilization before surgery. The complete treatment algorithm, agent selection, and monitoring guidance are in the full protocol.

Target: blood pressure <130/80 mm Hg seated, systolic >90 mm Hg standing; heart rate 60–70 bpm seated and 70–80 bpm standing.

References

DOI: 10.1210/jc.2014-1498

  • We recommend open resection for large (eg, >6 cm) or invasive pheochromocytomas to ensure complete tumor resection, prevent tumor rupture, and avoid local recurrence.
  • Calcium channel blockers are the most often used add-on drug class to further improve blood pressure control in patients already treated with α-adrenergic receptor blockers.
  • α-Methyl-paratyrosine (metyrosine) inhibits catecholamine synthesis and may be used in combination with α-adrenergic receptor blockers for a short period before surgery to further stabilize blood pressure to reduce blood loss and volume depletion during surgery.
  • Based on retrospective studies and institutional experience, a target blood pressure of less than 130/80 mm Hg while seated and greater than 90 mm Hg systolic while standing seems reasonable, with a target heart rate of 60–70 bpm seated and 70–80 bpm standing.
View source ↗